European Commission approves EYLUXVI (ALT-L9) by Alteogen
EYLUXVI is the second biosimilar approved by the European Commission for Alteogen, following the launch of the Herceptin biosimilar in China through its partner Qilu Pharmaceutical.
European Commission | 18/09/2025 | By Dineshwori
CuraTeQ Biologics Receives UK MHRA Approval for Trastuzumab Biosimilar Dazublys
CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys.
European Commission | 26/08/2025 | By Dineshwori
Pfizer and BioNTech's Updated COVID-19 Vaccine Secures EMA Nod, Awaits Final EU Approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Pfizer- BioNTech's LP.8.1-adapted monovalent COVID-19 vaccine in the European Union.
European Commission | 28/07/2025 | By Dineshwori
AbbVie Receives European Commission Approval of ELAHERE
ELAHERE is the first and only folate receptor alpha (FR?)-directed antibody drug conjugate (ADC) medicine approved in the European Union (EU), as well as Iceland, Liechtenstein, Norway, and Northern Ireland.
European Commission | 18/11/2024 | By Aishwarya | 180
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy